Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New clinical study supports flexibility in timing of administration for Sanofi SA's Lyxumia


Thursday, 5 Dec 2013 08:00am EST 

Sanofi SA:Says the results of a 24-week Phase IIIb clinical study showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day.Says these results indicate that lixisenatide can effectively lower blood sugar at either time of administration.Says the results also showed that a comparable reduction in body weight, regardless of the meal before which lixisenatide was administered, was achieved and the gastrointestinal tolerability was comparable regardless of time of administration, with no cases of severe hypoglycemia in either arm. 

Company Quote

75.98
-1.34 -1.73%
11:38am EDT